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Abstract
Background: Mass poisonings with methanol are rare but occur regularly both in developed and
in developing countries. Data from the poisoning episodes are often published, but follow-up-data
is scarce. We therefore conducted a six year follow-up study after the large methanol outbreak in
Estonia in September 2001.
Methods: Surviving victims from the outbreak were contacted and invited to an interview and a
clinical evaluation by an ophthalmologist and a physician. The patients that failed to respond were
searched for in the Estonian Register of Population and through their General Practitioner.
Results: During the outbreak in 2001, 86/111 hospitalized patients survived: 66 without sequelae
(Group I) and 20 with sequelae (Group II). Six years later, 26/86 were dead, 33/86 could not be
tracked down, and so only 27/86 of these were followed up and examined: 22/66 of the patients in
Group I, and 5/20 in Group II were found and examined. From Group I, 8/22 were identified with
new neurological impairment and 8/22 with new visual disturbances after discharge. From Group
II, visual disturbances (n = 4) and neurological impairment (n = 3) were still present in all patients.
Among the 26 dead, 19 were from Group I, and seven were from Group II. Alcohol intoxication
was the most frequent cause of death (7/26).
Conclusion: All sequelae were still present six years after the initial poisoning suggesting that
these were irreversible damages. On follow-up, apparently new neurological and visual
complications were identified in 36% and 36%, respectively. 35% of the patients initially discharged
with sequelae and 29% discharged without were dead six years later; 27% of them from alcohol
intoxication.
Background
Methanol is metabolized by the enzyme alcohol dehydro-
genase (ADH) in the liver, via formaldehyde to formic
acid, the latter being responsible for the adverse effects
seen in methanol poisoning. The toxicity evolves from a
combination of the metabolic acidosis (H+ production)
and an intrinsic toxicity from the formate anion itself
[1,2]. Treatment consists of buffer such as sodium bicar-
bonate to correct metabolic acidosis and antidote to
inhibit metabolism of methanol to its toxic metabolite,
formic acid [3,4]. If necessary, haemodialysis is supplied
to further correct the acidosis, and remove both methanol
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and formate [1,3,5-7]. In addition, folinic acid may
enhance the endogenous metabolism of formate [2].
Methanol poisonings occur as isolated episodes caused by
accidental or intentional ingestion, or epidemics. In the
latter situation a large number of victims are often
reported [8-10].
In September 2001, illegal spirits containing 50–100%
methanol were sold and consumed in the western part of
Estonia in the Pärnu region. Out of a total of 147 patients
admitted to hospital with suspicion of methanol poison-
ing, 36 did not have detectable serum methanol on
admission, leaving a total of 111 hospitalized patients
with verified methanol exposure. A total of 68 patients
died: 25 in the hospital, whereas 43 were found dead from
methanol poisoning outside the hospital. Thus, methanol
poisoning was verified in a total of 154 patients (Figure
1). Patients were mainly treated with NaHCO3 infusion,
ethanol infusion, dialysis and mechanical ventilation [9].
There is a lack of follow-up studies on methanol poisoned
patients. The only literature found on the topic was the
work done by Roe in 1943, where the visual disturbances
in methanol poisoned patients were followed the weeks
after discharge [11]. To evaluate the general outcome, the
mortality, the visual disturbances and the neurological
impairment after a methanol outbreak, we performed a
follow-up study six years after the initial incident.
Methods
Surviving victims from the methanol outbreak in 2001 in
Pärnu, Estonia, were traced through hospital records from
the former outbreak, and invited by letter and telephone
to an interview and a clinical evaluation. The patients that
failed to respond were searched for through the Estonian
Register of Population and their general practitioners. The
patients were after the 2001 outbreak classified into three
groups: Those who survived without sequelae (Group I),
those who survived with sequelae (Group II) and those
who died (Group III). There were 66 patients in Group I,
Overview of the methanol outbreak in Estonia in 2001 and the follow-up study in 2007 Figure 1
Overview of the methanol outbreak in Estonia in 2001 and the follow-up study in 2007.
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20 patients in Group II, where visual disturbances and
neurological impairment was the most common seque-
lae, and 25 patients in Group III [9].
The patients answered a questionnaire regarding their his-
tory of former diseases before and after the incident in
2001, as well as diseases at present (including diabetes).
They were questioned about their drinking habits before
and after the initial outbreak in 2001. Further, all prescrip-
tional medications used in 2001 and at present were reg-
istered.
The medical and the neurological examination were per-
formed by a physician, whereas the ophthalmological
examination was performed by an ophthalmologist: All
findings were compared to the clinical status at discharge
six years earlier. The data were categorized in a descrip-
tional manner, hence no further statistical analyzes were
performed.
The study was approved by Tallinn Medical Research Eth-
ics Committee, following an individual agreement from
all participating patients.
Results
After the outbreak in 2001, there were 86 survivors (66
without sequelae – Group I, and 20 with sequelae –
Group II). Six years later, 26 (30%) were dead (5 females
and 21 males), 33 (38%) were lost to follow-up, and so
only 27 (31%) were tracked and examined (all of the lat-
ter agreed to participate in the study): 22/66 (33%) of the
patients in Group I (6 females and 16 males), and 5/20
(25%) in Group II (1 female and 4 males) were among
these (Figure 1).
Since 2001, 8/22 in Group I – the survivors without
sequelae – were identified with neurological impairment
and 8/22 with visual disturbances (Table 1 [see Additional
file 1]). The latter complications were all revealed by an
ophthalmologist. None of the patients had diabetes. In
Group II – the survivors with sequelae – 18/20 had visual
disturbances at discharge in 2001. Six years later 4/18
were tracked and examined, visual disturbances were still
present in all of them.
The most common visual disturbances present at the time
of follow-up (both groups-present at discharge and appar-
ently acquired after discharge) were: Optical nerve atro-
phy, temporal pallor of the optic nerve head, visual field
defects, and loss of visual acuity (severe to deep blind-
ness). Further, 3/20 in Group II had neurological impair-
ment on discharge from hospital six years earlier and this
was still present, whereas one additional patient had
developed neurological impairment six years after the ini-
tial discharge (Table 1 [see Additional file 1]).
The clinical symptoms among the patients with neurolog-
ical impairment were the same in both groups (present at
discharge and acquired after discharge): Polyneuropathy
and encephalopathy (from light to severe), ataxic gait
(unstable walking), Romberg test positive (meaning that
they cannot stay upright with their eyes closed), or sensory
loss on the distal part of the legs (Table 1 [see Additional
file 1]).
Among the 26 who died after discharge from the poison-
ing episode in 2001, 19 were from Group I (survivors
without sequelae) and 7 were from Group II (survivors
with sequelae) (Figure 1). Alcohol intoxication (unknown
kind of alcohol and origin) was the most frequent cause
of death (7/26), whereas other causes of death were car-
diac reasons (6/26; including cardiomyopathy (n = 2) and
myocardial infarction (n = 2)), trauma (3/26), carbon
monoxide-poisoning (3/26) or pneumonia (2/26).
The status on follow-up after six years among the different
age-groups is shown in Figure 2: Only 11 patients were
tracked and found alive without sequelae. The mortality
was relatively evenly distributed in the different age
groups (approximately 30%), except from the age group
>60 years, where 50% were dead after six years. There were
relatively more patients lost to follow-up in the two
youngest age-groups (approximately 55%), vs. 45%
among the 50–60 year olds, and 21–28% among the rest.
Only a few of the patients who drank alcohol on a regular
basis before the methanol outbreak reduced their drink-
ing habits after the incidence: Among the patients from
Group II, 1/5 was still drinking alcohol in the same
amount and frequency as he did before the initial out-
break in 2001, whereas 2/5 had reduced their alcohol con-
sumption and 2/5 had stopped using alcohol completely.
Among the patients from Group I, 10/22 developed
sequelae  after  discharge (6 both VD and neurological
impairment (NI), 2 VD and 2 NI): There were fewer
patients who stopped drinking in this group (1/10) vs. the
ones who did not develop sequelae (5/12). 3 patients
were still drinking alcohol in the same amount and fre-
quency as before the methanol poisoning among both the
ones who acquired sequelae after discharge, and those
who did not. Regarding their "quality of life" and disabil-
ity, we found that 6/27 of those tracked six years later now
needed help in their activities of daily living.
Discussion
Despite efficient treatment [3], methanol poisoning has a
high morbidity and mortality [2,10,12,13]. Some patients
with methanol poisoning will probably remain unknown
in a large outbreak, either having lesser symptoms and
never being examined, or dying without the diagnosis ofBMC Clinical Pharmacology 2009, 9:5 http://www.biomedcentral.com/1472-6904/9/5
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methanol poisoning being suspected [10]. The prognosis
depends on the degree of metabolic acidosis [2,10,14].
Different findings on admission has been suggested as
poor prognostic factors, e.g. high S-methanol concentra-
tion [8,13], although others do not find this [10,12,15].
Coma on admission is generally considered a poor prog-
nostic sign [8,10,13], and recently, increased pCO2 in the
severely acidotic patient (lack of compensatory hyperven-
tilation) is suggested as a new marker [9,10]. The most fre-
quent sequelae found at discharge are visual disturbances
and neurological impairment of some kind.
This follow-up study was performed to evaluate the course
of the patients in the aftermath of a methanol poisoning
outbreak. We found that visual disturbances present at
discharge was still present six years later and were of the
same magnitude, supporting the findings from 1943 by
Roe [11]. In 8/22 patients discharged without visual dis-
turbances in 2001, these complications were found six
years later. Patients were all evaluated by an ophtalmolo-
gist, who considered the methanol poisoning to be the
likely cause: The main findings included optical nerve
atrophy, temporal pallor of the optic nerve head, concen-
trical reduction of the visual field, and loss of visual acuity
(Table 1 [see Additional file 1]). One likely explanation is
that many of those patients were discharged without a
clinical evaluation by an ophthalmologist. It may also
partly be explained by a gradual development of symp-
toms over time, making them symptomatic and possible
to measure, rather than a pure late onset complication.
Regardless, this raises the question whether this phenom-
enon is an under-reported feature also in other outbreaks.
Neurological impairment was generally increased during
these six years: As many as 8/22 patients discharged with-
out neurological impairment developed neurological
complications: The most likely reason for that is the con-
tinuous use of excess alcohol: There were fewer patients
who stopped drinking among the patients who developed
the neurological impairment.
There was a high death toll (30%), also among the
patients discharged alive from the outbreak in 2001. The
mortality was slightly higher among the ones in Group II
(discharged with sequelae) (35%), compared to the ones
in Group I (29%). The causes of death was dominated by
alcohol intoxication (27%), cardiac diseases (23%), and
traumas (19%), indicating that the this is an exposed and
vulnerable group: In 2001, all age groups were repre-
sented from below 30 to above 60 years old, but there was
Status on follow-up after six years (patients grouped according to their age in 2001) Figure 2
Status on follow-up after six years (patients grouped according to their age in 2001).
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an overrepresentation of frequent drinking, middle-aged
males [9]. The fact that only 12 patients was tracked and
found alive without sequelae six years later further sup-
ports this argument.
Generally, there was a high mortality in all age groups
(approximately 30%), with a higher mortality (50%)
among the oldest ones (>60 years) as expected. More
patients were lost to follow-up among the youngest
patients, but no obvious reasons for this were found.
Unfortunately, the drinking habits of many of the patients
did not improve: A lot of them were still using excessive
amounts of alcohol despite the serious methanol poison-
ing incident. This indicates that individuals affected by a
methanol outbreak may benefit from counselling and
other efforts aimed at reducing their alcohol abuse.
Conclusion
The morbidity and mortality of methanol poisoning
remains high, even after discharge from hospital. Likely
reasons for this are the patients themselves often being a
high-risk group with a high alcohol-attributable burden.
In this population, the death toll among the survivors
from the outbreak in 2001 was high even within the
youngest age-groups. Sequelae from methanol poisoning
are likely to persist or even progress (both visual distur-
bances and neurological impairment): Visual distur-
bances may be a feature developing over time, hence be an
under-estimated feature in methanol poisoned patients in
general. The risk of developing neurological impairment
seems to be higher if drinking habits are not changed.
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